Analytical Data
-
Gene name
GAD1/GAD67
- Application
-
Alternative Names
Glutamate Decarboxylase
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q99259
-
Expression Region
Met1~Leu594
-
Molecular Weight
69kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GAD1 (Glutamic Acid Decarboxylase 1) and GAD67 (Glutamic Acid Decarboxylase 2) are critical enzymes that catalyze the synthesis of gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the central nervous system. Abnormalities in GAD1/GAD67 expression have been implicated in various neuropsychiatric disorders, including schizophrenia, bipolar disorder, and epilepsy. Detailed studies of GAD1/GAD67 recombinant proteins are essential for understanding their biological functions, regulatory mechanisms, and role in neurotransmission. Furthermore, these proteins are critical for developing therapeutic strategies targeting GABAergic dysfunctions. By expressing GAD1 and GAD67 as recombinant proteins, researchers can investigate their enzymatic activity, physiological relevance, and potential interactions with other neuronal proteins. Such studies pave the way for designing novel drugs aimed at modulating GABA synthesis, offering new avenues for the treatment of disorders associated with GABA deficiency. The generation of high-purity recombinant GAD1/GAD67 provides a valuable tool for structural analyses, aiding in the determination of the protein's 3D conformation and the identification of its active sites. Additionally, it enables the exploration of post-translational modifications that may influence enzyme activity and stability. Enhanced understanding of GAD1/GAD67 functions, coupled with advancements in recombinant protein technology, holds significant promise for unraveling the complex pathophysiology of GABA-related disorders and advancing therapeutic innovation.
